Omeros Corporation enters its Q1 2026 earnings release — due after the close on May 14 — in a state of genuine short-selling pressure, with one of the tightest borrow markets in the small-cap pharma space and a short score that signals extreme positioning.
The most striking feature of the setup is how stretched the lending market has become. Availability has collapsed to less than 1% of short interest — roughly 0.70% — meaning nearly every share available to borrow is already out on loan. That reading has been at or near the 52-week floor for most of the past six weeks, touching zero availability repeatedly since early April. The cost to borrow, while still modest in absolute terms at around 1.1% annualised, has ticked up 12% over the past week after softening through most of April. Taken together, the borrow market signals that new short sellers face a near-impenetrable lending pool ahead of the print.
Short interest itself is heavy but has been coming off the highs. Short interest has eased to 22.1% of free float from a peak close to 24% in early April — a drop of roughly 10% over the past month, with the bulk of that reduction occurring in the last week (down about 4%). Days to cover runs at 13, implying it would take nearly three weeks of average trading volume to fully close out the short book. The ORTEX short score is 83.9 out of 100, ranking in the first percentile of the broader universe — one of the most extreme short setups in the market. Shorts are retreating, but they are retreating slowly, and the stock remains deeply in short-seller territory.
Options positioning tells a more bullish story. The put/call ratio has fallen to 0.31 — nearly two standard deviations below its 20-day average of 0.35 and close to the lowest reading of the past year. That ratio was running above 0.38 just three weeks ago. The rapid shift toward calls rather than puts since early May suggests options traders have been rotating into upside bets, possibly in anticipation of a catalyst from tomorrow's earnings release.
The one analyst covering OMER with a disclosed target — D. Boral Capital — maintained its Buy rating and $36 target as recently as April 21, a 144% premium to Tuesday's close of $14.76. HC Wainwright doubled its target to $40 back in January following news around YARTEMLEA. Coverage remains thin (two disclosed ratings, all bullish), so the Street view carries limited weight as a signal on its own. The bull case centres on accelerating demand for YARTEMLEA in TA-TMA and the buildout of reimbursement infrastructure; the bear case rests on limited real-world efficacy data and the potential for reimbursement friction. A permanent J-code from CMS is a positive but does not resolve the data questions. The EMA regulatory decision expected in mid-2026 is a further binary in the pipeline.
On ownership, the founder and CEO Gregory Demopulos sold 357,678 shares at $11.93 in February — a $4.3 million disposal — while his brother Peter Demopulos added 600,000 shares at roughly the same time. BlackRock and Vanguard both added meaningfully in their most recent filings, up 610,000 and 666,000 shares respectively. The founder selling into the January rally while passive institutions added is an ambiguous signal rather than a clear directional read.
The last earnings print on March 31 produced a 23% single-day gain and a further 12% over the following five days. Tomorrow's release is the next moment where that kind of short-squeeze dynamic could re-emerge — or where the shorts who remain at 22% of the float find more reason to stay.
See the live data behind this article on ORTEX.
Open OMER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
